Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03732703

Recruitment Status : Unknown

Verified September 2021 by Multiple Myeloma Research Consortium.
Recruitment status was: Recruiting

First Posted : November 7, 2018

Last Update Posted : September 10, 2021

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

AbbVie

Celgene Corporation

Eli Lilly and Company

Genentech, Inc.

Janssen, LP

Takeda

GlaxoSmithKline

Karyopharm Therapeutics Inc

Information provided by (Responsible Party):

Multiple Myeloma Research Consortium

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	February 10, 2022
Estimated Study Completion Date :	February 10, 2024

Publications:

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.

To Top